MT2018-35 A Randomized Phase 2 Study of Obinutuzumab for Prevention of Chronic Graft vs. HostDisease After Allogeneic Peripheral Blood Stem Cell Transplantation

Project: Research project

Project Details

Description

MT2018-35 A Randomized Phase 2 Study of Obinutuzumab for Prevention of Chronic Graft vs. Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation
StatusActive
Effective start/end date10/1/199/30/21

Funding

  • Dana-Farber Cancer Institute

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.